Stock Analysis
- United States
- /
- Pharma
- /
- NasdaqGM:ETON
Eton Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Eton Pharmaceuticals (NASDAQ:ETON) Full Year 2022 Results
Key Financial Results
- Revenue: US$21.3m (down 2.7% from FY 2021).
- Net loss: US$9.02m (loss widened by 361% from FY 2021).
- US$0.36 loss per share (further deteriorated from US$0.078 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Eton Pharmaceuticals EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) exceeded analyst estimates by 5.3%.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Eton Pharmaceuticals that you should be aware of.
What are the risks and opportunities for Eton Pharmaceuticals?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
Rewards
Trading at 39.3% below our estimate of its fair value
Earnings are forecast to grow 91.49% per year
Risks
Shareholders have been diluted in the past year
Further research on
Eton Pharmaceuticals
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:ETON
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
Excellent balance sheet with high growth potential.
